Apotex launched generic version of Plavix® an antiplatelet agent for treating thrombotic conditions which is already marketed by Bristol-Myers Squibb and Sanofi-Aventis after the proposed settlement between the parties were rejected. The analyst opinion article outlines the various strategies that big pharma has taken to remain competitive. The article also suggests that this sort of issues between big pharma and generic company could be concluded by entering into collaboration for big pharma’s authorized generic.